AstraZeneca chief attacks Pfizer’s £63bn takeover bid
AstraZeneca's chief executive has launched a staunch attack on Pfizer’s £63bn takeover plan, saying it would jeopardise its “fragile” but ambitious drug discovery programme.
Pascal Soriot declared the company would grow annual sales to more than $45bn by 2023 from the current $25.7bn thanks largely to its pipeline of new medicines being developed. It was just that process of creating new drugs that would be jeopardised by a takeover, he said.
“I have been through enough mergers to known a company is not a machine. It is a group of people. If you disrupt their work you can really have a negative impact very quickly.”
AstraZeneca has gone from a position of having 57 drugs in 2012 to 84 now, as it has moved quickly to boost its development programme. Analysts say that, as well as the UK tax status, is what attracted Pfizer to make its bid.
Mr Soriot said: “Our people are very experienced, motivated and excited about what we are doing. We believe we can make an impact on medicine at this time. We have recruited very talented people. When you do this you really want to remain focused on the job at hand. "
He added: "Any distraction, any disruption, could have a negative impact on our ability to develop these products. A pipeline is something that is very fragile. That is why we believe we are better off focused on what we are doing.”
His view chimes with those of many scientists who have spoken out against the huge disruption a takeover of one of Britain’s two key pharmaceuticals champions could have.
Dr Scott Gottlieb, an adviser to pharmaceuticals companies and resident fellow at the American Enterprise Institute, said: “You get really fundamental product breakthroughs when you have small groups of scientists working together on new areas of science over a period of many years. When companies do these mergers, it can break up these teams and break up the continuity.”
Mr Soriot said AstraZeneca’s shareholders had been supportive so far, adding: "We are in a race with many of our competitors to bring our products to the marketplace as quickly as possible. Anything that creates disruption has the potential to destroy value."
He was speaking just hours after the chief executive of top 10 AstraZeneca shareholder Aberdeen Asset Management backed the Labour leader Ed Miliband’s calls for a public interest investigation into the deal.
Aberdeen chief executive Martin Gilbert told The Independent: “AstraZeneca’s management has done a good job refocusing the business and as far as we’re concerned remaining independent remains a viable outcome.
“We do have to look at this in UK terms because it is so important for our research and development. It’s got to be about more than tax benefits.”
Earlier, he told the BBC: “Pfizer unfortunately has this reputation of being ruthless cost-cutters.”
Mr Soriot added that speed of decisionmaking was critical to bringing new drugs to market – a fleetness of foot that could be disrupted by a massive merger.
However, he declined to get pulled into the increasingly tense political atmosphere around the deal, although he acknowledged that he had been asked to participate in MPs’ select committee hearings. Both the business and science committees yesterday confirmed they would be conducting meetings with the industry including representatives from both Pfizer and AstraZeneca.
As anti-Semitic attacks rise, Grant Feller re-evaluates his identity
Savoury patisserie is a thing now
Meet the primary school where every day is National Poetry Day
Kirstie Allsopp has waded into the female fertility debate again
...and it wasn't caused by an asteroid crash, as first thought
Gillian Anderson lays into gender disparity in Hollywood
Striker ignored Brendan Rodger's request to applaud audience
- 1 Snoop Dogg and Jared Leto buy a stake in Reddit as A-list invests $50m
- 2 Prince held a Facebook Q&A and this is the only question he answered...
- 3 35,000 walrus gather on north-west Alaska beach 'for a rest'
- 4 Brad Pitt, on the moment he completely lost his temper with Clint Eastwood's son
- 5 A teacher speaks out: 'I'm effectively being forced out of a career that I wanted to love'
Stella McCartney apologises over controversial 'very ill' model picture on Instagram
Snoop Dogg and Jared Leto buy a stake in Reddit as A-list invests $50m
Prince held a Facebook Q&A and this is the only question he answered...
Brad Pitt, on the moment he completely lost his temper with Clint Eastwood's son
Cheryl Cole named 'the most dangerous celebrity' on the internet
Former Tory donor Arron Banks ups his Ukip donation to £1million following William Hague 'nobody' comment
Exclusive: 'Putin's Russia has been my biggest regret,' says Nato's outgoing Secretary General
The Osborne Ultimatum: Chancellor’s benefits freeze bombshell will affect ten million households
There’s no excuse for Dave Lee Travis’s behaviour, but we need to keep a sense of proportion
Mark Reckless becomes second Tory MP to defect to Ukip in a month
Should gay sex be illegal? 16% of Britons think so
- < Previous
- Next >
iJobs Money & Business
£18000 - £23000 per annum + Commission: SThree: Real Staffing are currently lo...
NEGOTIABLE: Austen Lloyd: TRUST ACCOUNTANT - KENTIf you are a Chartered Accou...
£18000 - £20000 per annum + OTE £30000: SThree: SThree are a global FTSE 250 b...
Highly Competitive Salary: Austen Lloyd: CITY - Law Costs Draftsperson - NICHE...